AstraZeneca to Invest $2 Billion in Summit Therapeutics, Backing China-Licensed Cancer Drug Sep 29, 2026 Life Science
ByteDance’s Anew Labs Emerges With $1.5B Valuation, Stirring New Questions Over AI Drug Discovery Sep 25, 2026 Life Science
Positive VK2735 Clinical Data: Can Viking Therapeutics Displace Eli Lilly and Novo Nordisk? Sep 23, 2026 Life Science
Iambic Therapeutics Files for U.S. IPO, Adding Another AI Drug-Discovery Startup to Nasdaq Pipeline Sep 22, 2026 Life Science, Technology
Can Novo Nordisk’s Anthropic Partnership Drive an AI-Powered Turnaround? Sep 16, 2026 Life Science, Technology
Eli Lilly Ramps Up Acquisitions to Diversify Beyond Weight-Loss Drug Dominance Sep 15, 2026 Life Science
Amgen vs. Vertex Pharmaceuticals: Value Stability vs. High-Growth Biotech Investment Plays Sep 14, 2026 Life Science
Novo Nordisk Scores Pediatric Weight-Loss Trial Win, Unlocking Contrarian Investment Value Sep 11, 2026 Life Science
Eli Lilly Is on an M&A Spree—Will the $2.88 Billion Merida Deal Be Enough to Diversify? Aug 31, 2026 Life Science
Rasonque’s Lightning Approval Validates Druckenmiller’s Bet on Revolution Medicines Aug 28, 2026 Life Science
